Patent · US Active

Compositions and methods for enhancing macrophage-mediated antibody guided cancer cell or tumor eradication

US11667900B2 · kind B2 · utility

0Cited by
1References
23Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 12, 2018
Grant dateJun 6, 2023
Priority date
Expiry dateJul 27, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/61
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are Shp2- and Spleen tyrosine kinase (Syk)-integrated sensing and actuating protein (iSNAP) (Shp2- and Syk-iSNAP) chimeric proteins comprising: a bi-phosphorylatable peptide, optionally a bisphosphoryl tyrosine-based activation (BTAM) motif; a Fluorescent Protein (FP) Förster Resonance Energy Transfer (FRET) (or FP FRET) pair or pair of motifs; a truncated Shp2 domain comprising an N-Src Homology 2(N-SH2) domain and a C-Src Homology 2(C-SH2) domain; and, a phosphatase (PTP) domain or a kinase domain. Provided are engineered cells and methods for cancer cell or tumor eradication, or for the treatment or amelioration of a cancer, tumor or dysfunctional cell, or for promoting an anti-cancer, anti-tumor or anti-dysfunctional cell inflammatory response, including enhancing macrophage-, monocyte-, microglia-, osteoclast-, Kupffer cell- or dendritic cell-mediated antibody- or monoclonal antibody (mAb)-guided cancer or dysfunctional cell or tumor eradication, amelioration, or treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.